echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Roche Trastuzumab Injection's marketing application was accepted by CDE

    Roche Trastuzumab Injection's marketing application was accepted by CDE

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 21, Roche's application for the marketing of trastuzumab injection (subcutaneous injection) was accepted by CDE, which means that this subcutaneous preparation will soon be available in China.

    The subcutaneously injected trastuzumab is a compound preparation composed of trastuzumab and recombinant human hyaluronidase.
    It was approved by the FDA in February 2019 for the treatment of adult metastatic breasts with HER2 overexpression Cancer, trade name: Herceptin Hylecta®.

    The US FDA approved the marketing of Herceptin Hylecta® based on the results of the following clinical trials:

    1) In a phase III HannaH study, neoadjuvant therapy and adjuvant therapy using Herceptin Hylecta® + chemotherapy were compared with intravenous Herceptin® + chemotherapy.
    The results showed that, compared with intravenous Herceptin®, subcutaneous injection of Herceptin Hylecta® achieved non-inferiority in both pharmacokinetics and clinical efficacy.

    2) The second study, SafeHER, is a prospective, two-cohort, non-randomized, international, open-label trial.
    Researchers evaluated the safety and tolerability of Herceptin Hylecta combined chemotherapy in 1864 HER2-positive breast cancer patients .
    The results of the study show that the safety of the new dosage form is consistent with the previous standard dosage form of trastuzumab.

    3) The third study, PrefHER, is a patient preference trial.
    240 patients received adjuvant Herceptin Hylecta treatment followed by intravenous trastuzumab treatment, or in the reverse order.
    The results showed that 86% of trial patients preferred the subcutaneous regimen.

    As a ready-to-use preparation, Herceptin Hylecta can be administered within 2-5 minutes, while the time required for intravenous infusion of Herceptin is 30-90 minutes, which greatly shortens the administration process.
    time consuming.
    After Herceptin Hylecta goes on the market in China, it will provide doctors and patients with a new choice to choose a treatment plan according to individual needs and preferences.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.